Michael Weiner of Abcam in Branford named 2016 Entrepreneur of the Year
In a ceremony December 13 at the CURE Annual Holiday Party at Alexion in New Haven, the 2016 CURE Entrepreneur of the Year award was presented to Dr. Michael Weiner, who is currently Vice President, Molecular Sciences, at Abcam in Branford.
In nominations for the award, Dr. Weiner was hailed by his peers as “a creative and prescient innovator” and “a self-starter with business, as well as scientific acumen.”
Dr. Weiner successfully founded and sold three companies, two of which were based in Branford (Affomix, acquired by Illumina in 2010; and AxioMx, acquired by Abcam in 2015). The technologies he developed at these companies, widely cited and utilized in the industry, include QuikChange Mutagenesis, next generation DNA sequencing, emulsion PCR, bead-based genotyping, biopanning, and better/cheaper/faster methods for the production of monoclonal antibodies.
Moreover, through his companies and his professional activities, during his 16 years living in Connecticut, Dr. Weiner has contributed time, energy, and resources to training and mentoring numerous bioscience and biobusiness professionals who are currently enriching the Connecticut bioscience cluster.
The annual CURE year end celebration, held for the first time at Alexion is an important networking event for the Connecticut bioscience community. In addition to Alexion, this year’s sponsors included Aerotek; AON; Connecticut Innovations; Elm Street Ventures; Fortunato Construction Group; Hallam-ICS; Shipman & Goodwin LLP; Ware, Fressola, Maguire & Barber LLP; Winstanley Enterprises and VWR.
The Entrepreneur of the Year award was established by CURE and the law firm of Shipman & Goodwin in 2013 to acknowledge the importance of showcasing unique accomplishments of entrepreneurs in the Connecticut community. The award recognizes individuals who are imaginative, passionate, and game-changers in Connecticut bioscience, and whose accomplishments would be heralded outside of Connecticut.
Upon receipt of this year’s award, Dr. Weiner said “With several Colleges and leading Universities close by, New Haven has been a great place to recruit the talent needed to develop biotech technologies. And meeting investors willing to take the risks needed for transformative research has been enabling.”
Dormer Stephen, a partner at Shipman & Goodwin, said “Dr. Weiner’s accomplishments and innovations within the Connecticut bioscience community are truly deserving of this award and we are proud to recognize him for his work.”
In her introductory remarks, Dr. Susan Froshauer, President and CEO of CURE, said, “We are honored to recognize a serial entrepreneur with the rare combination of deep science and business savvy.”